Background: Breast cancer (BC) remains one of the leading causes of cancer-related deaths worldwide, with early detection being essential for improving survival rates, treatment outcomes, and preventive women’s healthcare strategies. Artificial Intelligence (AI), particularly deep learning (DL) and machine learning (ML) algorithms, has emerged as a promising tool for improving the accuracy and efficiency of BC diagnosis. This systematic review explores the role of AI in early BC detection and its implications for preventive and patient-centered women’s healthcare. Methods: A comprehensive search was conducted in PubMed and Scopus for studies published between January 2015 and December 2025, following PRISMA guidelines. The search strategy included combinations of MeSH terms and free-text keywords related to artificial intelligence, machine learning, deep learning, BC screening, mammography, magnetic resonance imaging (MRI), ultrasound, and BC detection. Eleven studies involving approximately 148,170 participants were included. Methodological quality was assessed according to study design. Results: AI-driven diagnostic systems demonstrated improved accuracy, sensitivity, specificity, and efficiency compared with conventional approaches. AI applications in mammography and ultrasound reduced radiologists’ workload and healthcare costs while enhancing cancer detection rates, particularly in women with high breast density. AI models also showed potential in identifying metastases and predicting clinical outcomes, supporting more efficient patient management and follow-up care. Conclusions: AI-based tools represent a promising advancement in BC detection and screening efficiency. Their integration into BC screening programs may strengthen preventive women’s healthcare services and improve patient outcomes. However, further large-scale clinical validation and real-world implementation studies are required before widespread clinical implementation.
Breast cancer during pregnancy presents unique therapeutic challenges, as effective maternal treatment must be balanced against potential risks to fetal and neonatal health. This systematic review aims to evaluate current evidence regarding the safety and effectiveness of chemotherapy during pregnancy in women with breast cancer (BC). This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search was conducted in PubMed, Google Scholar, Scopus, and the Open Inter-university Consortium for Political and Social Research databases. Following the search and selection process, a total of 14 articles met the inclusion criteria. Risk of bias was assessed using design-specific Joanna Briggs Institute critical appraisal tools. The administration of specific chemotherapy regimens, mainly anthracyclines, after the first trimester was generally not associated with an apparent increase in congenital abnormalities or perinatal mortality. However, an increased risk of preterm birth was observed, with a substantial proportion of preterm deliveries being iatrogenic. Furthermore, available comparative evidence did not indicate substantially worse maternal oncological outcomes attributable to pregnancy itself. Taken together, these findings suggest that chemotherapy for BC during pregnancy can be administered with relative safety after the first trimester, within an individualized treatment approach and close collaboration among obstetricians, oncologists, and neonatologists. Nevertheless, further multicenter studies are required to fully elucidate long-term neonatal outcomes.